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Cerebral amyloid angiopathy (CAA) is characterized by the deposition of amyloid aggre-
gates in the walls of the cerebral vasculature. Recently, the development of molecular
imaging probes targeting CAA has been attracting much attention. We previously reported
the 99mTc-hydroxamamide (99mTc-Ham) complex with a bivalent benzothiazole scaffold as
a binding moiety for amyloid aggregates ([99mTc]BT2) and its utility for CAA-specific imag-
ing. However, the simultaneous generation of two radiolabeled complexes derived from the
geometric isomers was observed in the 99mTc-labeling reaction. It was recently reported
that the complexation reaction of 99Tc with N-methyl-substituted Ham provided a single
99Tc-Ham complex consisting of two N-methylated Ham ligands with marked stability. In
this article, we designed and synthesized a novel N-methylated bivalent 99mTc-Ham com-
plex ([99mTc]MBT2) and evaluated its utility for CAA-specific imaging. N-Methyl substitution
of [99mTc]BT2 prevented the generation of its isomer in the 99mTc-labeling reaction.
Enhanced in vitro stability of [99mTc]MBT2 as compared with [99mTc]BT2 was observed.
[99mTc]MBT2 showed very low brain uptake, which is favorable for CAA-specific imaging.
An in vitro inhibition assay using β-amyloid aggregates and in vitro autoradiographic exami-
nation of brain sections from a Tg2576 mouse and a CAA patient showed a decline in the
binding affinity for amyloid aggregates due to N-methylation of the 99mTc-Ham complex.
These results suggest that the scaffold of the 99mTc-Ham complex may play important roles
in the in vitro stability and the binding affinity for amyloid aggregates.
Introduction
Cerebral amyloid angiopathy (CAA) is defined as the deposition of amyloid aggregates, most
commonly β-amyloid peptide (Aβ), in the media and adventitia of arteries and, less often,
capillaries of the brain[1–3]. CAA is a sporadic or familial disorder and is common in the
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elderly brain, with an age-related prevalence and significant increase with age[4]. CAA is pres-
ent in nearly all Alzheimer’s disease (AD) brains[4], and severe CAA is present in approxi-
mately 25% of AD brains[5], while fewer than 50% of CAA cases meet the pathologic criteria
for AD[6]. CAA can cause fatal intracerebral hemorrhage (ICH) and vascular cognitive
impairment[3,7,8], and is also associated with small vessel diseases such as white matter hyper-
intensity and cerebral microbleeds[3,9,10].
A definitive CAA diagnosis can be performed based on only histological findings of brain
tissue, obtained by autopsy or brain biopsy[11]. Although computed tomography (CT) and
magnetic resonance imaging (MRI) without any probe have commonly been used as noninva-
sive and usefulmodalities to diagnose CAA-associated ICH[12,13], they detect intracerebral
bleeding as a surrogate marker of CAA. These indirect diagnostic techniques cannot shed light
on the etiology of the sign, making it unlikely to perform disease-specificdiagnoses. In con-
trast, positron emission tomography (PET) and single photon emission computed tomography
(SPECT) can provide information on the localization of amyloid aggregates, while CT and
MRI provide the anatomical information. Therefore, PET and SPECT have been utilized as
major in vivo imaging techniques to carry out the noninvasive diagnosis of amyloidoses. Over
the past few decades, research on imaging of Aβ aggregates constituting senile plaque in AD
brains using PET and SPECT tracers has made marked progress[14–19].
Several groups have reported on the detection of cerebrovascular amyloid depositions using
[11C]PIB, which is the most commonly used Aβ-imaging probe[20–22]. However, due to high-
level efficiencywith the penetration of the blood-brain barrier (BBB), [11C]PIB is believed to
visualize amyloid depositions in the whole brain, indicating that it detects senile plaque as a
background signal in cases of CAA diagnosis.
With the aim of CAA-specific imaging, some groups, in addition to our group, have
reported PET and SPECT imaging probes targeting CAA[23–27].We previously reported a
series of 99mTc-hydroxamamide (99mTc-Ham) complexes with a bivalent amyloid ligand as
imaging probes targeting CAA[28]. The bivalent 99mTc-Ham complex, [99mTc]BT2 including
two benzothiazole scaffolds as the binding moiety, showed the specific detection of CAA on ex
vivo autoradiographic examination. However, the radiolabeling reaction of [99mTc]BT2 caused
the simultaneous generation of two geometric isomers that have different biological features,
including binding affinity for Aβ aggregates. Thipyapong et al. recently reported that the 99Tc
complexation reaction of N-methyl-substituted Ham rendered a single 99Tc-Ham complex
consisting of twoN-methylated Ham ligands with marked stability[29]. On the basis of this
previous report, we applied the concept to the novel design of 99mTc-Ham complexes.
We herein designed and synthesizedN-methyl-substituted [99mTc]BT2 ([99mTc]MBT2),




All reagents were obtained commercially and used without further purification unless other-
wise indicated. PIB was purchased from ABX (Saxony, Germany). Na99mTcO4 was purchased
fromNihon Medi-Physics Co., Ltd. (Tokyo, Japan) or obtained from a commercial
99Mo/99mTc generator (Ultra-Techne Kow; FUJIFILMRI Pharma Co., Ltd., Tokyo, Japan).
W-Prep 2XY (Yamazen, Osaka, Japan) was used for silica gel column chromatography on a Hi
Flash silica gel column (40 μm, 60 Å, Yamazen, Osaka, Japan). 1H NMR spectra were recorded
on a JNM-ECS400 (JEOL, Tokyo, Japan) with tetramethylsilane (TMS) as an internal standard.
Coupling constants are reported in Hertz. Multiplicity was defined as singlet (s), doublet (d),
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triplet (t), or multiplet (m). Mass spectra were obtained on a SHIMADZULCMS-2020
(SHIMADZU, Kyoto, Japan). Reversed-phase high-performance liquid chromatography
(RP-HPLC) was performedwith a Shimadzu system (SHIMADZU, an LC-20AT pump with
an SPD-20A UV detector, λ = 254 nm) with a Cosmosil C18 column (Nacalai Tesque, Kyoto,
Japan, 5C18-AR-II, 4.6 × 150 mm) using a mobile phase [10 mM phosphate buffer (pH 7.4)/
acetonitrile = 3/2 (0 min) to 3/7 (30 min)] delivered at a flow rate of 1.0 mL/min.
Animals
Animal experiments were conducted in accordance with our institutional guidelines and were
approved by the Kyoto University Animal Care Committee.Male ddYmice were purchased
from Japan SLC, Inc. (Shizuoka, Japan). Female Tg2576 mice and wild-typemice were pur-
chased from Taconic Farms, Inc. (New York, USA). Animals were fed standard chow and had
free access to water. All efforts were made to minimize suffering.
Human brain tissues
Experiments involving human subjects were performed in accordance with the relevant guide-
lines and regulations and were approved by the ethics committee of Kyoto University. Informed
consent was obtained from all subjects in this study. Postmortem brain tissues from autopsy-





Compound 1 was prepared according to our previous report[30].
Fig 1. Chemical structure of N-methyl-substituted [99mTc]BT2 ([99mTc]MBT2).
doi:10.1371/journal.pone.0163969.g001
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Synthesis of (Z)-2-(4-(dimethylamino)phenyl)-N’-((ethoxycarbonyl)oxy)benzo[d]thiazole-
6-carboximidamide (2).
To a solution of 1 (50 mg, 0.16 mmol) in DMF (10 mL) were added ethyl chlorocarbonate
(18 μL, 0.19 mmol) and triethylamine (44 μL, 0.32 mmol). The reactionmixture was stirred at
room temperature for 1 h. Water (50 mL) was added, and the mixture was extracted with chlo-
roform (30 mL × 2). The organic layers were combined, dried over MgSO4, and filtered. Evapo-
ration of the filtrate gave a residue, which was purified by silica gel chromatography (ethyl
acetate/hexane = 10/1) to give 16 mg of 2 (25% yield). 1H NMR (400 MHz, DMSO-d6) δ 8.35
(s, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.92 (d, J = 8.8 Hz, 2H), 7.77 (d, J = 8.4 Hz, 1H), 6.90 (s, 2H),




A solution of 2 (87 mg, 0.23 mmol) in 1 M NaOH (aq)/DMF (1/1, 40 mL) was stirred at
room temperature for 1 h. After the addition of acetate (5 mL), the mixture was neutralized
with saturated NaHCO3 water (20 mL), and extractedwith chloroform (50 mL × 2). The
organic layers were combined, dried over MgSO4, and filtered. Evaporation of the filtrate gave
a residue, which was purified by silica gel chromatography (ethyl acetate/hexane = 5/1) to give
15 mg of 3 (20% yield). 1H NMR (400 MHz, DMSO-d6) δ 8.50 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H),




Iodomethane (5.5 μL, 0.088 mmol) and potassium carbonate (18 mg, 0.13 mmol) were
added to a solution of 3 (15 mg, 0.044 mmol) in DMF (5 mL). The reactionmixture was stirred
at room temperature for 3 h. After the addition of water (50 mL), the mixture was extracted
with chloroform (30 mL × 2). The organic layers were combined, dried over MgSO4, and fil-
tered. Evaporation of the filtrate gave a residue, which was purified by silica gel chromatogra-
phy (ethyl acetate/hexane = 1/1) to give 9 mg of 4 (58% yield). 1H NMR (400 MHz, DMSO-d6)
δ 8.48 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.95 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.4 Hz, 1H), 6.85 (d,
J = 8.4 Hz, 2H), 3.28 (s, 3H), 3.05 (s, 6H). MS (ESI)m/z 353 [MH+].
Synthesis of (Z)-2-(4-(dimethylamino)phenyl)-N’-hydroxy-N-methylbenzo[d]thiazole-
6-carboximidamide (MBTHam, 5).
A solution of 4 (15 mg, 0.043 mmol) in 1 M NaOH (aq)/DMF (1/1, 10 mL) was stirred at
90°C for 14 h. The reactionmixture was neutralizedwith 1 MHCl (aq) while it was cooled in
an ice bath. After extractionwith chloroform, the organic layers were combined, dried over
MgSO4, and filtered. The filtrate was concentrated, and the residue was purified by silica gel
chromatography (chloroform/methanol = 10/1) and then RP-HPLC [10 mM phosphate buffer
(pH 7.4)/acetonitrile = 3/2 (0 min) to 3/7 (30 min)] to give 5 mg of 5 (36% yield). 1H NMR
(400 MHz, DMSO-d6) δ 9.67 (s, 1H), 8.08 (s, 1H), 7.92 (d, J = 8.4 Hz, 1H), 7.90 (d, J = 8.8 Hz,
2H), 7.49 (d, J = 8.4 Hz, 1H), 6.84 (d, J = 8.8 Hz, 2H), 5.84–5.79 (m, 1H), 3.03 (s, 6H), 2.63 (d,
J = 5.2 Hz, 3H). MS (ESI)m/z 327 [MH+].
Radiolabeling
To a solution of 1 or 5 (0.2 mg) in acetate/ethanol (1/4, 200 μL) were added 100 μL of
Na99mTcO4 solution and 15 μL of tin(II) tartrate hydrate solution [2 mg of tin(II) tartrate
hydrate (7.5 μmol) dissolved in water (2.5 mL)]. The reactionmixture was incubated at room
temperature for 30 min and purified by RP-HPLC. The 99mTc-Ham complexes were analyzed
99mTc-Complex with N-Methyl Substituted Ham as Probe for CAA Imaging
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by analytical RP-HPLC on a Cosmosil C18 column (5C18-AR-II, 4.6 × 150 mm) using a mobile
phase [10 mM phosphate buffer (pH 7.4)/acetonitrile = 3/2 (0 min) to 3/7 (30 min)] at a flow
rate of 1.0 mL/min. The radioactivity of the 99mTc-labeled compounds was recorded for 30
min.
Stability in murine plasma
The 99mTc-Ham complex (740 kBq) was added to freshly prepared murine plasma (200 μL)
collected from ddYmice (male, 5 weeks old). After incubating the solution at 37°C for 0.5, 1,
and 2 h, acetonitrile (200 μL) was added. Subsequently, they were centrifuged (4,000 g, 5 min),
and the supernatant was analyzed by RP-HPLC.
Assessment of the BBB permeability
A saline solution (100 μL) of the 99mTc-Ham complex (20 kBq) containing EtOH (10 μL) was
injected directly into the tail vein of ddYmice (male, 5 weeks old). The mice were sacrificed at
2, 10, 30, and 60 min postinjection.The brain was removed and weighed, and radioactivity was
measured using a γ counter (Wallac 1470 Wizard; PerkinElmer, Massachusetts, USA). The %
injected dose (ID)/g of samples was calculated by comparing the sample counts with the count
of the diluted initial dose.
Inhibition assay using Aβ aggregates in solution
A solid form of Aβ(1–42) was purchased from the Peptide Institute (Osaka, Japan). Aggrega-
tion was carried out by gently dissolving the peptide (0.25 mg/mL) in phosphate-buffered
saline (PBS) (pH 7.4). The solution was incubated at 37°C for 42 h with gentle and constant
shaking. A mixture containing 50 μL of Aβ(1–42) aggregates (final conc., 1.25 μg/mL), 50 μL of
the 99mTc-Ham complex (8 kBq), 50 μL of PIB (final conc., 64 pM-125 μM in EtOH), and
850 μL of 30% EtOH was incubated at room temperature for 3 h. The mixture was filtered
throughWhatman GF/B filters (Whatman, Kent, U.K.) using a Brandel M-24 cell harvester
(Brandel, Maryland, USA), and the radioactivity of the filters containing the bound 99mTc-
Ham complex was measured using a γ counter (Wallac 1470 Wizard). Values for the half-max-
imal inhibitory concentration (IC50) were determined from displacement curves using Graph-
Pad Prism 5.0 (GraphPad Software, Inc., California, USA).
In vitro autoradiography of Tg2576 mouse brain sections
A Tg2576 transgenic mouse (female, 28 months old) and a wild-typemouse (female, 28
months old) were used as an ADmodel and an age-matched control, respectively. After each
animal had been sacrificedby decapitation, the brain was immediately removed, embedded in
Super CryoembeddingMedium (SCEM) compound (SECTION-LAB Co., Ltd., Hiroshima,
Japan), and then frozen in a dry ice/hexane bath. Frozen sections were prepared at a 10-μm
thickness. Each slide was incubated with a 50% EtOH solution of the 99mTc-Ham complex
(370 kBq/mL) at room temperature for 1 h. For blocking experiments, adjacent sections were
incubated with a 50% EtOH solution of the 99mTc-Ham complex (370 kBq/mL) in the presence
of nonradioactive PIB (500 μM). The sections were washed in 50% EtOH for 1.5 min two times
and exposed to a BAS imaging plate (Fuji Film, Tokyo, Japan) for 6 h. Autoradiographic images
were obtained using a BAS5000 scanner system (Fuji Film). After autoradiographic examina-
tion, the same sections were stained by thioflavin-S to confirm the presence of Aβ plaques. For
thioflavin-S staining, the sections were immersed in a 100 μM thioflavin-S solution containing
99mTc-Complex with N-Methyl Substituted Ham as Probe for CAA Imaging
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50% EtOH for 3 min, washed in 50% EtOH for 1 min two times, and examined using a micro-
scope (BIOREVO BZ-9000; Keyence Corp., Osaka, Japan) equipped with a GFP-BP filter set.
In vitro autoradiography of human CAA brain sections
Six-micrometer-thick serial human brain sections of paraffin-embeddedblocks were used for
autoradiography. To completely deparaffinize the sections, they were incubated in xylene for
30 min two times and in 100% EtOH for 1 min two times. Subsequently, they were subjected to
1-min incubation in 90% EtOH and 1-min incubation in 70% EtOH, followed by a 5-min wash
in water. Each slide was incubated with a 50% EtOH solution of the 99mTc-Ham complex (370
kBq/mL) at room temperature for 1 h. The sections were washed in 50% EtOH for 3 min two
times and exposed to a BAS imaging plate (Fuji Film) for 2 h. Autoradiographic images were
obtained using a BAS5000 scanner system (Fuji Film). After autoradiographic examination,
the adjacent sectionwas immunostained by an antibody against Aβ(1–40) to confirm the pres-
ence of Aβ depositions. For immunohistochemical staining of Aβ(1–40), the sectionwas auto-
claved for 15 min in 0.01 M citric acid buffer (pH 6.0) to activate the antigen. After three 5-min
incubations in PBS-Tween 20 (PBST), it was incubated with anti-Aβ(1–40) primary antibody
(BA27; Wako, Osaka, Japan) at room temperature overnight. Subsequently, it was incubated in
PBST for 5 min three times, and incubated with biotinylated goat anti-mouse IgG (Wako) at
room temperature for 3 h. After three 5-min incubations in PBST, the sectionwas incubated
with Streptavidin-Peroxidase complex at room temperature for 30 min. After three 5-min
incubations in PBST, it was incubated with diaminobenzidine (Merck, Hesse, Germany) as a




The precursor for [99mTc]MBT2 (MBTHam, 5) was prepared in four steps from the precursor
for [99mTc]BT2 (BTHam, 1) according to a previous report (Fig 2)[31]. BTHam was prepared
according to our previous report[30]. Reaction of BTHam with ethyl chlorocarbonate pro-
vided compound 2, which was cyclized to compound 3 in alkaline solution. After methylation
with iodomethane to give compound 4, it was decyclized by heating in alkaline solution to
MBTHam.
Radiolabeling
The 99mTc labeling reaction was performed by the complexation reaction using the Ham pre-
cursor, 99mTc-pertechnetate, and tin(II) tartrate hydrate as a reducing agent (Fig 3)[30]. The
Fig 2. Synthetic route for MBTHam.
doi:10.1371/journal.pone.0163969.g002
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99mTc complexation reaction with MBTHam rendered a single peak at the retention time of
13.6 min on RP-HPLC, while the reaction with BTHam provided two peaks at the retention
times of 11.5 and 14.3 min (Fig 4). This suggests that N-methylation of the Ham ligand would
be a useful strategy to obtain a single 99mTc-Ham complex by preventing the isomerism, as
described in a previous report[29].We defined the specific isomer of [99mTc]BT2 with a shorter
retention time on RP-HPLC as [99mTc]BT2A, and the other as [99mTc]BT2B.
Stability in murine plasma
The in vitro stability of [99mTc]MBT2 and [99mTc]BT2 was evaluated by incubating them in
murine plasma at 37°C for 0.5, 1, and 2 h (Fig 5 and Table 1). For [99mTc]BT2, the radiochemical
Fig 3. Radiosynthesis of [99mTc]BT2 and [99mTc]MBT2.
doi:10.1371/journal.pone.0163969.g003
Fig 4. Radiochromatograms of [99mTc]BT2 (A) and [99mTc]MBT2 (B).
doi:10.1371/journal.pone.0163969.g004
Fig 5. Percent radiochemical purity of [99mTc]MBT2 and [99mTc]BT2 as a function of time.
doi:10.1371/journal.pone.0163969.g005
99mTc-Complex with N-Methyl Substituted Ham as Probe for CAA Imaging
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purities of the two radiolabeled isomers were combined and expressed. [99mTc]MBT2 main-
tained a higher stability than [99mTc]BT2 until 2 h, indicating that N-methyl substitution of the
99mTc-Ham complex enhanced its stability, as demonstrated in a previous report[29].
Assessment of the BBB permeability
Biodistribution experiments were performed in order to assess the brain uptake of [99mTc]
MBT2 in normal mice (Table 2). To reduce the binding to Aβ aggregates in the brain cortex,
CAA-specific imaging probes need not to show high-level penetration of the BBB[28,29].
[99mTc]MBT2 displayed very low brain uptake (0.35%ID/g at 2 min postinjection), as well as
[99mTc]BT2B (0.37%ID/g at that time)[28], indicating that [99mTc]MBT2 has a favorable prop-
erty for CAA imaging. It was suggested that the methyl group introduced into the hydroxama-
mide moiety of [99mTc]MBT2 may not contribute to its brain entry.
Inhibition assay using Aβ aggregates in solution
To evaluate the binding affinity for Aβ aggregates of [99mTc]MBT2 and [99mTc]BT2, we per-
formed an inhibition binding assay with PIB as a competitive ligand. A fixed concentration of
Aβ aggregates and the 99mTc-Ham complex were incubated with increasing concentrations of
nonradioactive PIB in solution. The binding affinity of 99mTc-complexes was expressed as val-
ues for the half-maximal inhibitory concentration (IC50) determined from displacement curves
(Fig 6). When calculating the IC50 values from the displacement curves, PIB showed IC50 val-
ues of 0.56, 2.80, and 5.78 μM in the presence of [99mTc]MBT2, [99mTc]BT2A, and [99mTc]
BT2B, respectively (Table 3). A decrease in the binding affinity for Aβ aggregates due toN-
methylation of the 99mTc-Ham complex was observed.
In vitro autoradiography of Tg2576 mouse brain sections
The binding of [99mTc]MBT2 and [99mTc]BT2 to Aβ plaques in brain sections from Tg2576
mice was evaluated by in vitro autoradiography. Since Tg2576 mice overproduce Aβ aggregates
in the brain, they have been commonly used to evaluate the specific binding affinity of probes
for Aβ aggregates in a variety of experiments in vitro and in vivo[19,28,30]. As shown in
Table 1. In vitro stability of [99mTc]MBT2 and [99mTc]BT2 in murine plasma.
Radiochemical purity (%)a at given incubation times
Complex 0.5 h 1 h 2 h
[99mTc]MBT2 96.4 ± 3.3 93.5 ± 2.5 92.5 ± 2.5
[99mTc]BT2 89.5 ± 3.1 87.4 ± 2.2 86.0 ± 4.6
aValues are the mean ± standard deviation of three experiments for each point.
doi:10.1371/journal.pone.0163969.t001
Table 2. Radioactivity of extracted brain tissues after intravenous injection of [99mTc]MBT2 and [99mTc]BT2B in normal micea.
Time after injection (min)
Complex 2 10 30 60
[99mTc]MBT2 0.35 ± 0.04 0.21 ± 0.02 0.15 ± 0.01 0.11 ± 0.01
[99mTc]BT2Bb 0.37 ± 0.11 0.20 ± 0.04 0.10 ± 0.02 0.05 ± 0.01
aExpressed as %injected dose per gram. Each value is the mean ± standard deviation of five animals
bData from our previous study (Ref. 28).
doi:10.1371/journal.pone.0163969.t002
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Fig 7A, 7E and 7I, no radioactive spots were observed in the wild-typemouse brain sections.
[99mTc]BT2A and [99mTc]BT2B showed intensive radioactive spots in the Tg2576 mouse brain
sections, while [99mTc]MBT2 displayed only a few spots indistinctly compared with [99mTc]
BT2A and [99mTc]BT2B (Fig 7B, 7F and 7J). These radioactive spots were consistent with Aβ
depositions confirmed by the fluorescent staining in the same sections with thioflavin-S, a dye
commonly used to stain Aβ plaques (Fig 7C, 7G and 7K, red arrowheads). However, some Aβ
depositions were not labeled with [99mTc]MBT2 in spite of the fact that [99mTc]BT2A and
[99mTc]BT2B labeled almost all Aβ depositions. The results of in vitro autoradiography well
reflected those of the inhibition assay. Moreover, the labeling of Aβ plaques with 99mTc-labeled
compounds was blocked to a large extent with an excess of nonradioactive PIB, confirming the
specific binding to Aβ plaques in the mouse brain (Fig 7D, 7H and 7L). A decline in the binding
affinity for Aβ plaques by chemical modification of the 99mTc-Ham complex was suggested in
autoradiograms, as observed in the inhibition assay.
In vitro autoradiography of human CAA brain sections
An in vitro autoradiographic examination of human CAA brain sections was carried out in
order to confirm binding affinity for Aβ plaques deposited in the human brain (Fig 8). The dis-
tribution of Aβ deposits was confirmed by immunohistochemical staining of Aβ (Fig 8B),
showing that [99mTc]MBT2 moderately labeled Aβ deposits in a brain section from a CAA
patient. However, as observed in the inhibition assay and autoradiographic examination using
Fig 6. Displacement curves of 99mTc-Ham complexes from the inhibition assay for binding PIB to Aβ
aggregates. Values are the mean ± standard error of six independent experiments. aData from our previous
study (Ref. 30).
doi:10.1371/journal.pone.0163969.g006
Table 3. Half-maximal inhibitory concentration (IC50, μM) for the binding of PIB to Aβ aggregates
determined using 99mTc-Ham complexes as ligands.
Complex IC50 of PIB (μM)a
[99mTc]MBT2 0.56 ± 0.08
[99mTc]BT2Ab 2.80 ± 0.32
[99mTc]BT2Bb 5.78 ± 0.53
aValues are the mean ± standard error of the mean of six independent experiments
bData from our previous study (Ref. 30).
doi:10.1371/journal.pone.0163969.t003
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the mouse brain sections, it was suggested that [99mTc]MBT2 showed lower binding affinity as
compared with that of the parent 99mTc-Ham complex. These results suggest that the core of
chelate in the 99mTc-Ham complex may contribute to the binding affinity for aggregated amy-
loid peptides.
Conclusions
Herein, we designed and synthesized a novel N-methyl-substituted 99mTc-Ham complex with a
bivalent amyloid ligand and evaluated its fundamental utility as an imaging probe targeting
CAA. In the 99mTc complexation reaction,N-methyl substitution of the Ham ligand abolished
the generation of the geometric isomer, forming a single 99mTc-labeled compound. The in vitro
stability in murine plasma of [99mTc]MBT2 was higher than that of [99mTc]BT2. An ex vivo
biodistribution study showed that both [99mTc]MBT2 and [99mTc]BT2 could hardly penetrate
the BBB in normal mice. An in vitro inhibition assay with Aβ aggregates and in vitro autoradi-
ography using brain sections from a Tg2576 mouse and a CAA patient showed a decrease in
the binding affinity for Aβ aggregates due to chemical modification of the 99mTc-Ham com-
plex. These results suggest that the scaffold of the 99mTc-Ham complex may play crucial roles
in the stability in murine plasma and binding affinity for amyloid aggregates. These findings
also provide important information for the molecular design of novel imaging probes based on
the 99mTc-Ham complex targeting amyloid aggregates in the future.
Fig 7. In vitro autoradiograms of mouse brain sections labeled with 99mTc-Ham complexes. The
sections are from wild-type (A, E, and I) and Tg2576 (B, F, and J) mice. The same Tg2576 mouse brain
sections are stained with thioflavin-S (C, G, and K). Blocking studies with PIB are also performed using the
adjacent brain sections (D, H, and L). aData from our previous study (Ref. 30).
doi:10.1371/journal.pone.0163969.g007
Fig 8. In vitro autoradiograms of human brain sections from a patient with CAA. The sections are
labeled with [99mTc]MBT2 (A) and [99mTc]BT2B (C). The adjacent brain section is immunostained with an
antibody against β-amyloid (B). aData from our previous study (Ref. 28).
doi:10.1371/journal.pone.0163969.g008
99mTc-Complex with N-Methyl Substituted Ham as Probe for CAA Imaging
PLOS ONE | DOI:10.1371/journal.pone.0163969 September 30, 2016 10 / 12
Acknowledgments
This research was supported by a grant from the Japan Society for the Promotion of Science
(JSPS) through the “Funding Program for Next GenerationWorld-Leading Researchers
(LS060),” initiated by the Council for Science and Technology Policy (CSTP), JSPS KAKENHI




Funding acquisition: SI MO.
Writing – original draft: SI MO.
Writing – review& editing: SI MOHWMYHI-UMI HS.
References
1. Biffi A, Greenberg SM. Cerebral Amyloid Angiopathy: A Systematic Review. J Clin Neurol. 2011; 7
(1):1–9. doi: 10.3988/jcn.2011.7.1.1 PMID: 21519520
2. Gahr M, Nowak DA, Connemann BJ, Schonfeldt-Lecuona C. Cerebral amyloidal angiopathy-A disease
with implications for neurology and psychiatry. Brain Res. 2013; 1519:19–30. doi: 10.1016/j.brainres.
2013.04.052 PMID: 23651976
3. Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol. 2011; 70
(6):871–80. doi: 10.1002/ana.22516 PMID: 22190361
4. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm. 2002;
109(5–6):813–36. doi: 10.1007/s007020200068 PMID: 12111471
5. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, et al. Cerebral amyloid angiopathy in the
brains of patients with Alzheimer’s disease: The CERAD experience, part XV. Neurology. 1996; 46
(6):1592–6. PMID: 8649554
6. Vinters HV. Cerebral Amyloid Angiopathy—a Critical-Review. Stroke. 1987; 18(2):311–24. PMID:
3551211
7. Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive
impairment. Stroke. 2004; 35(11 Suppl 1):2616–9. doi: 10.1161/01.STR.0000143224.36527.44 PMID:
15459438
8. Mehndiratta P, Manjila S, Ostergard T, Eisele S, Cohen ML, Sila C, et al. Cerebral amyloid angiopathy-
associated intracerebral hemorrhage: pathology and management. Neurosurg Focus. 2012; 32(4):E7.
doi: 10.3171/2012.1.FOCUS11370 PMID: 22463117
9. Holland CM, Smith EE, Csapo I, Gurol ME, Brylka DA, Killiany RJ, et al. Spatial distribution of white-
matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke.
2008; 39(4):1127–33. doi: 10.1161/STROKEAHA.107.497438 PMID: 18292383
10. Smith EE. Leukoaraiosis and stroke. Stroke. 2010; 41(10 Suppl):S139–43. doi: 10.1161/
STROKEAHA.110.596056 PMID: 20876490
11. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy:
Validation of the Boston Criteria. Neurology. 2001; 56(4):537–9. doi: 10.1212/WNL.56.4.537 PMID:
11222803
12. Walker DA, Broderick DF, Kotsenas AL, Rubino FA. Routine use of gradient-echo MRI to screen for
cerebral amyloid angiopathy in elderly patients. AJR Am J Roentgenol. 2004; 182(6):1547–50. doi: 10.
2214/ajr.182.6.1821547 PMID: 15150006
13. Zhan RY, Tong Y, Shen JF, Lang E, Preul C, Hempelmann RG, et al. Study of clinical features of amy-
loid angiopathy hemorrhage and hypertensive intracerebral hemorrhage. J Zhejiang Univ Sci. 2004; 5
(10):1262–9.doi: 10.1631/jzus.2004.1262 PMID: 15362199
14. Becker GA, Ichise M, Barthel H, Luthardt J, Patt M, Seese A, et al. PET quantification of 18F-florbeta-
ben binding to β-amyloid deposits in human brains. J Nucl Med. 2013; 54(5):723–31. doi: 10.2967/
jnumed.112.107185 PMID: 23471310
99mTc-Complex with N-Methyl Substituted Ham as Probe for CAA Imaging
PLOS ONE | DOI:10.1371/journal.pone.0163969 September 30, 2016 11 / 12
15. Choi SR, Golding G, Zhuang ZP, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: A
PET agent for Aβ plaques in the brain. J Nucl Med. 2009; 50(11):1887–94. doi: 10.2967/jnumed.109.
065284 PMID: 19837759
16. Lundqvist R, Lilja J, Thomas BA, Lotjonen J, Villemagne VL, Rowe CC, et al. Implementation and vali-
dation of an adaptive template registration method for 18F-flutemetamol imaging data. J Nucl Med.
2013; 54(8):1472–8. doi: 10.2967/jnumed.112.115006 PMID: 23740104
17. Nelissen N, Van Laere K, Thurfjell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of
the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with proba-
ble Alzheimer disease. J Nucl Med. 2009; 50(8):1251–9. doi: 10.2967/jnumed.109.063305 PMID:
19617318
18. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid
deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F 18). J Nucl Med. 2010;
51(6):913–20. doi: 10.2967/jnumed.109.069088 PMID: 20501908
19. Zhang W, Oya S, Kung MP, Hou C, Maier DL, Kung HF. F-18 Polyethyleneglycol stilbenes as PET
imaging agents targeting Aβ aggregates in the brain. Nucl Med Biol. 2005; 32(8):799–809. doi: 10.
1016/j.nucmedbio.2005.06.001 PMID: 16253804
20. Dierksen GA, Skehan ME, Khan MA, Jeng J, Nandigam RN, Becker JA, et al. Spatial relation between
microbleeds and amyloid deposits in amyloid angiopathy. Ann Neurol. 2010; 68(4):545–8. doi: 10.
1002/ana.22099 PMID: 20865701
21. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, et al. Imaging of amyloid bur-
den and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007; 62(3):229–34. doi: 10.1002/
ana.21164 PMID: 17683091
22. Ly JV, Donnan GA, Villemagne VL, Zavala JA, Ma H, O’Keefe G, et al. 11C-PIB binding is increased in
patients with cerebral amyloid angiopathy-related hemorrhage. Neurology. 2010; 74(6):487–93. doi:
10.1212/WNL.0b013e3181cef7e3 PMID: 20142615
23. Jaruszewski KM, Curran GL, Swaminathan SK, Rosenberg JT, Grant SC, Ramakrishnan S, et al. Mul-
timodal nanoprobes to target cerebrovascular amyloid in Alzheimer’s disease brain. Biomaterials.
2014; 35(6):1967–76. doi: 10.1016/j.biomaterials.2013.10.075 PMID: 24331706
24. Jia JH, Cui MC, Dai JP, Liu BL. 99mTc(CO)3-Labeled benzothiazole derivatives preferentially bind cere-
brovascular amyloid: Potential use as imaging agents for cerebral amyloid angiopathy. Mol Pharm.
2015; 12(8):2937–46. doi: 10.1021/acs.molpharmaceut.5b00209 PMID: 26065726
25. Nabuurs RJ, Rutgers KS, Welling MM, Metaxas A, de Backer ME, Rotman M, et al. In vivo detection of
amyloid-β deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer’s
disease. PLoS One. 2012; 7(6):e38284. doi: 10.1371/journal.pone.0038284 PMID: 22675537
26. Zha Z, Choi SR, Ploessl K, Lieberman BP, Qu W, Hefti F, et al. Multidentate 18F-polypegylated styryl-
pyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA). J Med Chem. 2011;
54(23):8085–98. doi: 10.1021/jm2009106 PMID: 22011144
27. Zha Z, Song J, Choi SR, Wu Z, Ploessl K, Smith M, et al. 68Ga-Bivalent polypegylated styrylpyridine
conjugates for imaging Aβ plaques in cerebral amyloid angiopathy. Bioconjug Chem. 2016; 27
(5):1314–23. doi: 10.1021/acs.bioconjchem.6b00127 PMID: 27045547
28. Iikuni S, Ono M, Watanabe H, Matsumura K, Yoshimura M, Kimura H, et al. Imaging of cerebral amy-
loid angiopathy with bivalent 99mTc-hydroxamamide complexes. Sci Rep. 2016; 6:25990. doi: 10.1038/
srep25990 PMID: 27181612
29. Thipyapong K, Uehara T, Tooyama Y, Braband H, Alberto R, Arano Y. Insight into technetium amidox-
ime complex: Oxo technetium(V) complex of N-substituted benzamidoxime as new basic structure for
molecular imaging. Inorg Chem. 2011; 50(3):992–8. doi: 10.1021/ic101714q PMID: 21226472
30. Iikuni S, Ono M, Watanabe H, Matsumura K, Yoshimura M, Harada N, et al. Enhancement of binding
affinity for amyloid aggregates by multivalent interactions of 99mTc-hydroxamamide complexes. Mol
Pharm. 2014; 11(4):1132–9. doi: 10.1021/mp400499y PMID: 24673484
31. Xu LC, Nakayama M, Harada K, Kuniyasu A, Nakayama H, Tomiguchi S, et al. Bis(hydroxamamide)-
based bifunctional chelating agent for 99mTc labeling of polypeptides. Bioconjug Chem. 1999; 10(1):9–
17. doi: 10.1021/bc980024j PMID: 9893958
99mTc-Complex with N-Methyl Substituted Ham as Probe for CAA Imaging
PLOS ONE | DOI:10.1371/journal.pone.0163969 September 30, 2016 12 / 12
